Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1

Status

Terminated 3Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Head & Neck 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 96Lung Neoplasms 38Neoplasms 10Mesothelioma, Malignant 9Mesothelioma 8Adenocarcinoma of Lung 8Small Cell Lung Carcinoma 7Neoplasm Metastasis 7Thoracic Neoplasms 5Recurrence 5Lung Diseases 5Carcinoma 5Respiratory Tract Neoplasms 4Carcinoma, Bronchogenic 4Brain Neoplasms 4Respiratory Tract Diseases 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Neoplasms by Site 3Neoplasms by Histologic Type 3NSCLC 3Head and Neck Neoplasms 3Bronchial Neoplasms 3Adenocarcinoma, Bronchiolo-Alveolar 3Adenocarcinoma 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Non-small-cell Lung Cancer With Somatic EGFR Mutations 2Neoplasms, Nerve Tissue 2Melanoma 2

Interventions

Carboplatin 4Sunitinib 3Rituximab 3Pemetrexed 3ponatinib 2pembrolizumab 2osimertinib 2Vincristine 2Prednisone 2Gemcitabine 2Etoposide 2Doxorubicin 2Cyclophosphamide 2ricolinostat 1pralsetinib 1pomalidomide 1nilotinib 1linifanib 1ibritumomab tiuxetan 1emvododstat 1atezolizumab 1Temozolomide 1Taxes 1Sorafenib 1Papanicolaou Test 1Paclitaxel 1Melphalan 1Irinotecan 1Interleukin-2 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Neoplasms by Histologic Type × Pemetrexed × Clear all
NCT04222972 2026-03-05

AcceleRET-Lung

Hoffmann-La Roche

Phase 3 Terminated
223 enrolled 18 charts
Head & NeckThoracic

Adenocarcinoma, Bronchial Diseases, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT05241873 2025-02-10

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

Blueprint Medicines Corporation

Phase 1 Terminated
103 enrolled
CNSThoracic

Adenocarcinoma, Brain Neoplasms, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT05153408 2023-06-18

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Blueprint Medicines Corporation

Phase 1 Terminated
20 enrolled
Thoracic

Adenocarcinoma, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡